D&D Pharmatech Reports Positive 48-Week Histology for DD01
27 May 2026 //
PHARMIWEB
Neuraly Supports Phase 2 Trial of NLY01 for Progressive MS
05 May 2026 //
PHARMIWEB
D&D Pharmatech Completes Enrollment for DD01 Phase 2 Trial in MASH
03 Feb 2025 //
BUSINESSWIRE
D&D Pharmatech Initiates Phase 2 Trial For Obesity Treatment DD01
21 Aug 2024 //
BUSINESSWIRE
D&D Granted Fast Track Designation from FDA for DD01 for the NASH/MASH
02 Apr 2024 //
BUSINESSWIRE
D&D Pharmatech Announces Rapid, Clinically Significant Reductions in Liver Fat
02 May 2023 //
BUSINESSWIRE
Neuraly points to younger patients as Parkinson`s bet fails
27 Mar 2023 //
FIERCE BIOTECH

Market Place
Sourcing Support